MINIMAL RESIDUAL DISEASE
Clinical trials for MINIMAL RESIDUAL DISEASE explained in plain language.
Never miss a new study
Get alerted when new MINIMAL RESIDUAL DISEASE trials appear
Sign up with your email to follow new studies for MINIMAL RESIDUAL DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to wipe out stubborn leukemia cells
Disease control OngoingThis study tests whether adding pembrolizumab (an immunotherapy) to standard tyrosine kinase inhibitors (TKIs) can eliminate leftover leukemia cells in people with chronic myeloid leukemia (CML). About 40 adults with stable disease but detectable cancer markers will receive the c…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 17, 2026 12:56 UTC
-
Engineered immune cells take on tough blood cancers
Disease control OngoingThis early-phase study tests a treatment that uses a patient's own immune cells, modified to recognize and attack cancer cells, for adults with B-cell blood cancers that have returned or not responded to standard therapy. The treatment is given with chemotherapy and sometimes an …
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated May 17, 2026 12:45 UTC
-
New radiation combo aims to boost transplant success in tough leukemias
Disease control TerminatedThis early-stage study tests a new way to prepare the body for a donor stem cell transplant in people with high-risk leukemia or myelodysplastic syndrome (MDS). It combines targeted radiation (TMLI) with two chemotherapy drugs to kill cancer cells and make room for healthy donor …
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New drug cocktail aims to tame deadly transplant complication in blood cancer patients
Disease control OngoingThis study tests whether adding a drug called cyclophosphamide after a stem cell transplant can lower the risk of graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. The trial includes 35 adults with various blood cancers or sever…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 05, 2026 11:54 UTC
-
Engineered t cells take aim at Hard-to-Treat leukemias
Disease control OngoingThis early-phase study tests a new type of immunotherapy for people with certain leukemias that have come back or not responded to standard treatments. The therapy uses a patient's own or a donor's immune cells that are genetically modified to recognize and attack cancer cells ca…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 05, 2026 11:52 UTC